Clinical Trial Update: Presatovir in Lung Transplant (LT) Recipients With Respiratory Syncytial Virus (RSV) Infection [Phase 2]

View source ↗

Summary

Phase 2 clinical trial update for presatovir in lung transplant recipients with RSV infection completed, with results posted in 2018.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Respiratory Syncytial Virus Disease
• Respiratory Syncytial Virus Infection in Lung Transplant Recipients

Drugs mentioned

• Presatovir (GS-5806)

Snippet

Sponsor: Gilead Sciences | Conditions: Respiratory Syncytial Virus (RSV) | Phase 2 | Status: COMPLETED | Results posted: 2018-11-28